The table below shows Adaptive Biotechnologies Corp's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$45.99M
-$95.21M
-$156.32M
-$183.94M
-$192.73M
-$149.68M
Capital expenditure
$2.96M
$3.66M
$10.70M
$16.35M
$61.75M
$18.80M
Investing cash flow
$37.95M
$77.79M
$129.65M
$2.90M
$181.21M
-$117.04M
Dividends paid
-
-
-
-
-
ADPT operating cash flow (10-K history)
Adaptive Biotechnologies Corp reported operating cash flow of -$45.99M for fiscal year 2025. That is up 51.7% from -$95.21M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$34.86M (FY 2017) to -$45.99M. Figures come from the company's audited annual reports as filed with the SEC.
